Premium
Role of oral pentosan polysulphate in the reduction of local side effects of BCG therapy in patients with non‐muscle‐invasive bladder cancer: a pilot study
Author(s) -
Yadav Suresh,
Tomar Vinay,
Yadav Sher Singh,
Priyadarshi Shivam,
Banerjee Indraneel
Publication year - 2016
Publication title -
bju international
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.773
H-Index - 148
eISSN - 1464-410X
pISSN - 1464-4096
DOI - 10.1111/bju.13489
Subject(s) - dysuria , medicine , group b , bladder cancer , visual analogue scale , placebo , overactive bladder , urology , urinary system , cancer , gastroenterology , anesthesia , alternative medicine , pathology
Objective To assess the role of oral pentosan polysulphate ( PPS ) in the reduction of bacille Calmette‐Guérin ( BCG )‐related local side effects in patients with high grade Ta/T1 non‐muscle‐invasive bladder cancer ( NMIBC ). Patients and Methods A total of 32 symptomatic patients receiving BCG instillation were randomized into three groups: group A received placebo (vitamin B complex tablet) thrice daily; group B received PPS 100 mg thrice daily; and group C received PPS 100 mg once daily and placebo (vitamin B complex tablet) twice daily for 6 weeks. A visual analogue scale ( VAS ) score for bladder pain, Overactive Bladder‐Validated 8 Question Screener ( OAB ‐V8) scores and dysuria were evaluated in the three groups before and during each weekly visit for BCG instillation. Results The mean ± sd post‐treatment VAS scores were significantly lower in groups B (4.4 ± 1.2) and C (5.8 ± 0.8) than in group A (8 ± 0.4). In addition, the post‐treatment VAS score was significantly lower in group B than in group C ( P <0.01). The mean post‐treatment OAB ‐V8 score was significantly lower only in group B (decreased from 15.5 to 9.7). Dysuria decreased in groups B and C but persisted in group A. Conclusion The present study shows that oral PPS (100 mg) thrice daily is effective in relieving BCG ‐related local side effects.